 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Fate Therapeutics
FATE
conference date: August 12, 2025 press release only
| 2025 | |||
| Fate Therapeutics Q4 2024 |
Fate Therapeutics Q1 2025 |
Fate Therapeutics Q2 2025 |
|
| March 5, 2025 | May 13, 2025 | August 12, 2025 | |
| 2024 | |||
| Fate Therapeutics Q4 2023 |
Fate Therapeutics Q1 2024 |
Fate Therapeutics Q2 2024 |
Fate Therapeutics Q3 2024 |
| Feb. 26, 2024 | May 9, 2024 | Aug. 13, 2024 | Nov. 12, 2024 |
| 2023 | |||
| Fate Therapeutics Q4 2022 |
Fate Therapeutics Q1 2023 |
Fate Therapeutics Q2 2023 |
Fate Therapeutics Q3 2023 |
| Feb. 28, 2023 | May 3, 2023 | Aug. 8, 2023 | Nov. 8, 2023 |
Fate Therapeutics (FATE) is a clinical-stage biotechnology company specializing in therapies for cancer.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BLRX |
| BMY |
| BOLD |
| CCCC |
| CLDX |
| CBIO |
| BMY |
| FATE |
| GILD |
| GLYC |
| ILMN |
| INO |
| IONS |
| LGND |
| MCHP |
| MRNA |
| REGN |
| RNA |
| RXRX |
| SAGE |
| SANA |
| SUPN |
| VRTX |
| VSTM |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2024 William P. Meyers